EMERALD: Phase III trial of elacestrant (RAD1901) vs endocrine therapy for previously treated ER+ advanced breast cancer.

Bardia, Aditya

EMERALD: Phase III trial of elacestrant (RAD1901) vs endocrine therapy for previously treated ER+ advanced breast cancer. [electronic resource] - Future oncology (London, England) Oct 2019 - 3209-3218 p. digital

Publication Type: Clinical Trial Protocol; Journal Article

1744-8301

10.2217/fon-2019-0370 doi


Female
Humans
Middle Aged
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Breast Neoplasms--drug therapy
Estrogen Receptor alpha--metabolism
Follow-Up Studies
Fulvestrant--administration & dosage
International Agencies
Prognosis
Prospective Studies
Survival Rate
Tetrahydronaphthalenes--administration & dosage
Randomized Controlled Trials as Topic
Multicenter Studies as Topic